Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 239 results for "julie masow"

FDA approves Novartis drug Odomzo® (sonidegib) for locally ad...

/PRNewswire/ --Novartis today announced the US Food and Drug Administration (FDA) has approved Odomzo ® (sonidegib, formerly LDE225) 200 mg capsules for the treatment of adult patients with locally advanced basal cell carcinoma (laBCC) that has ... Town Hall, 6 days ago
[x]  

Witchdoctor rapes teenage client

Tendai Rupapa Senior Court Reporter A 71-year-old self-styled witchdoctor allegedly drugged a 17-year-old girl who had visited his house for consultations before raping her, the court heard on Wednesday. The victim, who was experiencing marital ...
 Zimbabwe Daily2 weeks ago
PR Newswire

Novartis' new heart failure medicine LCZ696 approved by FDA to reduce risk of cardiovascular death and heart failure hospitalization; now called Entresto (sacubitril/valsartan)

/PRNewswire/ --Novartis announced today that the US Food and Drug Administration (FDA) has approved Entresto (sacubitril/valsartan) tablets, previously known as LCZ696, to reduce the risk of cardiovascular death and hospitalization for heart ...
 RCL Advisors3 weeks ago Novartis gains FDA approval for Promacta® providing new option for children, ages 6 and older, with chronic ITP, a rare blood disorder  Industrial Info Financials1 month ago 6/11/15 - Novartis gains FDA approval for Promacta® providing new option for children, ages 6 and older, with chronic ITP, a rare blood disorder  Pharmacy Choice1 month ago
[x]  
MSN News US

FDA Approves Blockbuster Heart Drug

Novartis Pharmaceuticals new heart failure drug called Entresto, which is , earned FDA approval on Tuesday six weeks before the agency's priority review action date when the decision was expected. The drug has been hyped as a multi-blockbuster by ...
 MSN News US3 weeks ago Novartis Earns FDA Approval For New $5B 'Blockbuster' Drug For Heart Failure Called Entresto And Reveals $12.50-A-Day Price  International Business Times3 weeks ago

Feds want Novartis to cough up $3.4B in damages, fines in kickback case

'; if(pArray.length >= 4) { i=2; } else if(pArray.length >= 3) { i=2; inline = ''; } else if(pArray.length >= 2) { i=1; inline = ''; } else if(pArray.length === 1) { i=0; inline = ''; } $('#librarydrawer_story_container script').each(function() { ...
 FiercePharma4 weeks ago Unions accuse Novartis of 'sham' patent fight to delay Sun's Gleevec generics  FiercePharma1 month ago
Investing.com

U.S. seeks up to $3.35 billion in Novartis kickback lawsuit

NEW YORK, June 30 (Reuters) - The United States says Novartis AG should pay as much as $3.35 billion in damages and civil fines because the Swiss drugmaker used kickbacks to boost sales of two drugs covered by Medicare and Medicaid. In ...
 CNBC1 month ago US seeks up to $3.35 billion from Novartis over alleged kickbacks to boost Exjade, Myfortic sales  FirstWord Pharma1 month ago US seeks up to US$3.35 billion in Novartis kickback lawsuit  Channel NewsAsia1 month ago
[x]  
USA Today

Skyrocketing drug prices leave cures out of reach for some patients

UP NEXT 03 Doctors and researchers are excited about new therapies derived from the study of the human genome that hold the promise of curing multiple forms of cancer using the patients own DNA to undo cancer cells. Mary Lee, USA TODAY Many ...
 USA Today1 month ago

Novartis presents new data at WCD that shows significant efficacy of Cosentyx® in patients with psoriasis of the palms, soles of feet and nails

/PRNewswire/ --Novartis announced today that Cosentyx ® (secukinumab) met the primary endpoints in two new clinical studies, showing superior efficacy compared to placebo in patients with psoriasis of the palms, soles of feet and nails, all of ...
 Industrial Info Financials1 month ago
[x]  

Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma

/PRNewswire/ -- Novartis is highlighting data from an ongoing Phase II clinical study of CTL019, an investigational chimeric antigen receptor (CAR) T cell therapy, that indicate its potential in the treatment of specific types of hard-to-treat ...
 Bloomberg1 month ago
[x]  

Novartis presents new data at ASCO for Zykadia and combination of Tafinlar® and Mekinist® in certain NSCLC patients with unmet needs

/PRNewswire/ --Novartis today announced new data from two Phase II studies of Zykadia (ceritinib), as well as one Phase II study of Tafinlar ® (dabrafenib) in combination with Mekinist ® (trametinib) in certain patients with non-small cell lung ...
 Reliance Trust1 month ago
[x]  
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less